Oncolys BioPharma Inc. [4588.T]
TOKYO, May 27 (Pulse News Wire) – Oncolys BioPharma Inc. (4588.T) announced today that it received a notice of intention to grant a patent for the endoscopic administration method of its tumor-dissolving virus OBP-301 in Europe.
This follows previous patents granted in Japan in 2025 and 2026. The European Patent Office's notification signifies their intent to issue a patent based on the current application. The patent covers broad applications of adenoviruses for tumor dissolution without limiting cancer types.
It allows potential expansion of OBP-301’s indications and applicability to OBP-702. Previously, the patent was limited to Japan but now extends coverage to key European countries such as the UK, France, and Germany. The patent validity period remains until May 2040, consistent with existing Japanese patents.
The impact on Oncolys BioPharma's fiscal 2026 December quarter earnings is expected to be minor.
🟢 Confidence: High AI-translated content.